PROCEPT BioRobotics

This question reflects a misunderstanding of the entity type. PROCEPT BioRobotics Corp is an operating medical device company, not an investment firm. Capital allocation decisions rest with the executive leadership team and board of directors, led by CEO Reza Zadno. Significant strategic investments, such as M&A or large-scale manufacturing expansions, require board approval per standard public-company governance.

PROCEPT operates a razor-and-blades revenue model uncommon in large-scale surgical robotics. Hospitals and surgery centers purchase the AquaBeam console as a capital equipment item, then consume a single-use disposable handpiece and sterile water cartridge for each procedure performed. The linkage between installed systems and recurring handpiece revenue generates high-margin recurring income once a facility reaches steady-state utilization — which typically takes three to six quarters post-installation.

Competition spans multiple benign prostatic hyperplasia treatment modalities. In surgical robotics, the closest comparable is the da Vinci SP system from Intuitive Surgical for simple prostatectomy. In the broader benign prostatic hyperplasia procedure market, PROCEPT competes against transurethral resection equipment vendors such as Olympus and Karl Storz, as well as laser-based platforms from Boston Scientific and Lumenis. The firm's key differentiation claim is the avoidance of thermal energy, which reduces collateral tissue damage.

The AquaBeam system received FDA 510(k) clearance in December 2017 for benign prostatic hyperplasia treatment in prostates up to 80 cubic centimeters. That limitation was removed in September 2023 with an FDA clearance for prostates up to 150 cubic centimeters, covering nearly all anatomically resectable prostates (per FDA's 510(k) database). The system also holds CE Mark in Europe and regulatory nods from Japan's PMDA and Korea's MFDS.

Revenue comes from two streams: one-time console sales and recurring disposables (handpiece plus accessories) used per procedure. The global benign prostatic hyperplasia treatment market was estimated at roughly $5 to $7 billion in 2023; the device subsegment represents around $3 to $4 billion of that (per SVB Leerink and Goldman Sachs published estimates). PROCEPT captures a growing but still single-digit share, with the conversion from legacy transurethral resection procedures representing the primary growth vector.

No. PROCEPT BioRobotics Corp is a Nasdaq-listed operating company (ticker: PRCT) that designs, manufactures, and sells surgical robotic systems to urology providers. It is not a family office, single-family office, or investment fund of any kind. Any interpretation of this entity as a private capital allocator is a false classification. It would appear in an allocator's due-diligence context only as a public equity long position.

The pivotal WATER study compared Aquablation with AquaBeam to standard transurethral resection in 181 patients across 17 centers in 9 countries. Published in the Journal of Urology in 2018, the trial met its primary non-inferiority endpoint and showed a statistically significant reduction in the rate of ejaculatory dysfunction — the most common quality-of-life side effect — at 6 months (per Wasserstein et al., 2018). Five-year follow-up data presented at the 2023 AUA meeting confirmed durable symptom improvement with a low retreatment rate.